NanoRepro AG
OTC: NNGRF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Lisa Jungst
- Employees
- 17
- Headquarters
- Marburg, Germany
- IPO year
- 2021
- Market cap
- $164.3M
- Website
- https://www.nanorepro.com
Loading NNGRF…
Loading profile data…Frequently asked questions about NNGRF
What does NanoRepro AG (NNGRF) do?
NanoRepro AG specializes in the conception, production, and global distribution of swift diagnostic assays and nutritional supplements. These offerings cater to both individual consumers and healthcare professionals, operating primarily from Germany. Their diagnostic portfolio encompasses diverse health sectors, including reproductive health, ge...
Where does NNGRF trade?
NanoRepro AG (NNGRF) trades on the Other OTC.
What sector is NNGRF in?
NanoRepro AG (NNGRF) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.
Who is the CEO of NanoRepro AG?
Lisa Jungst is the chief executive officer of NanoRepro AG (NNGRF).
Where is NanoRepro AG headquartered?
NanoRepro AG is headquartered in Germany.
Does NNGRF pay a dividend?
Yes — NanoRepro AG (NNGRF) paid a trailing twelve-month dividend of USD 0.15 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did NNGRF go public?
NanoRepro AG (NNGRF) completed its initial public offering in 2021.